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Involvement of cell-derived extracellular particles, coined as matrix vesicles (MVs), in 
biological bone formation was introduced by Bonucci and Anderson in mid-1960s. In 
1983, Anderson et al. observed similar structures in atherosclerotic lesion calcification 
using electron microscopy. Recent studies employing new technologies and high- res-
olution microscopy have shown that although they exhibit characteristics similar to 
MVs, calcifying extracellular vesicles (EVs) in cardiovascular tissues are phenotypically 
distinct from their bone counterparts. EVs released from cells within cardiovascular 
tissues may contain either inhibitors of calcification in normal physiological conditions 
or promoters in pathological environments. Pathological conditions characterized by 
mineral imbalance (e.g., atherosclerosis, chronic kidney disease, diabetes) can cause 
smooth muscle cells, valvular interstitial cells, and macrophages to release calcifying 
EVs, which contain specific mineralization-promoting cargo. These EVs can arise from 
either direct budding of the cell plasma membrane or through the release of exosomes 
from multivesicular bodies. In contrast, MVs are germinated from specific sites on 
osteoblast, chondrocyte, or odontoblast membranes. Much like MVs, calcifying EVs 
in the fibrillar collagen extracellular matrix of cardiovascular tissues serve as calcifi-
cation foci, but the mineral that forms appears different between the tissues. This 
review highlights recent studies on mechanisms of calcifying EV formation, release, 
and mineralization in cardiovascular calcification. Furthermore, we address the MV–EV 
relationship, and offer insight into therapeutic implications to consider for potential 
targets for each type of mineralization.
Keywords: calcification, atherosclerosis, aortic stenosis, hyperphosphatemia, extracellular vesicles, matrix 
vesicles
BACKGROUND
Bonucci reported the appearance of “roundish bodies” in initiation of the calcification process 
in guinea pig and rat tibial–femoral epiphyseal plates in 1967 (1). One year later, Anderson used 
electron microscopy on tissue sections to demonstrate vesicular structures in the mouse carti-
lage epiphysis (2). Subsequent studies have suggested that mineralization depends on secretion 
of matrix vesicles (MVs), with diameter of 30–400  nm (3, 4), from chondrocytes, osteoblasts, 
odontoblasts, tenocytes, and cementoblasts (5). MVs released from specific sites on cell mem-
branes [apical microvilli (3)] exhibit similar cytosolic and plasma membrane profiles apparent 
in their cell of origin (6). Compared to their parent cells, MVs carry augmented levels of acidic 
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lipids such as phosphatidylserine (PS) and sphingomyelin, but 
diminished levels of neutral phospholipids of phosphatidylcho-
line and lysophospholipids (5). Chondrocytes residing in the 
epiphyseal plate experience hypoxic conditions due to presence 
of collagen fibrils and proteoglycans, which restrict oxygen and 
nutrients delivery (7). Development of blood microvessels into 
this zone creates oxidative stress caused by the sudden elevation 
in nutrients, oxygen, calcium ions (Ca2+), and phosphate ions 
(Pi) (8). This process leads to enrichment of mitochondria with 
Ca2+, which results in secretion of Ca2+-loaded vesicles into the 
cytosol. It has been proposed that the formation of complexes 
between PS and Ca2+ either with Pi or annexins in these vesicles, 
diminishes the Ca2+ level within the cytosol, expedites actin 
depolymerization, and consequently leads MVs to pinch-off 
from the cell and release into the extracellular environment 
(8, 9). Of note, apoptotic bodies originating from apoptotic cell 
membrane rearrangement during terminal stage of mineraliza-
tion in epiphyseal plate differs from active formation and release 
of MVs (10). Released MVs interact with glycosaminoglycans 
and initiate extracellular mineral deposition (11).
Chondrocyte differentiating factors such as thyroxine 
(T3), bone morphogenetic protein 6, retinoic acid, and Indian 
hedgehog may give rise to MV generation by inducing changes 
in cell phenotype (12). Osteogenic cell types abundantly express 
annexin I, II, IV, V, VI, and VII. Annexins function as voltage-
gated channels or Ca2+-binding agents, mediate inflammation 
responses, and regulate structural properties of both cells and 
MVs membranes (4, 11, 13). The most abundant proteins in MVs 
are annexins II, V, and VI, which can accelerate the calcification 
process by either providing required Ca2+ for mineralization or 
partaking in PS–Ca2+-annexin complexes (14). Additionally, 
other membrane proteins such as calbindin D9k can provide Ca2+ 
for MVs (15).
Pyrophosphate (PPi), which originates from nucleotide 
pyrophosphatase phosphodiesterase (NPP1) hydrolysis of 
nucleoside triphosphates, inhibits mineralization. Progressive 
ankylosis (ANK) carries PPi into extracellular milieu. Tissue 
non-specific alkaline phosphatase (TNAP, on the outer leaflet 
of MV membranes) hydrolyzes PPi into free phosphate (Pi) and 
provides free Pi for complexing with Ca2+ and mineral formation 
(5, 7, 16). Type III Na/Pi transporters (PiT-1) on the MV mem-
brane facilitate Pi internalization. Bone morphogenetic protein 
2 and parathyroid hormone upregulate expression of these 
transporters (7). Additionally, MVs contain phosphatases and 
membrane phosphohydrolases, such as TNAP, AMPase, ATPase, 
nucleoside triphosphate pyrophosphohydrolase (NTPPase, 
NPP1, and PC-1), and PHOSPHO-1 that elevate the intrave-
sicular Pi concentration within the MVs (5, 17). This highly 
ions concentrated environment, adjacent to the MV membrane, 
where Ca2+ and Pi meet, provokes calcium phosphate precipita-
tion followed by an increase in pH and mineral stabilization. 
Membrane–mineral associations are mediated by PS located on 
the luminal side of the MV lipid bilayer. PS is an anionic phospho-
lipid with tendency to bind Ca2+. The complexes of PS–Ca2+–Pi 
may serve as initial nuclei for hydroxyapatite precipitation (7, 13, 
18). Studies have also suggested that the mineralization process 
can begin intracellularly with contribution of pre-nucleation 
clusters within endosomes, which initiate mineralization in 
order to maintain Ca2+ and Pi in homeostatic concentration and 
fulfill energy trade-off (5).
Matrix vesicles are equipped with matrix metalloproteases 
(MMPs) that degrade and remodel the ECM (3, 19). Particularly, 
MMP-2, MMP-3, MMP-9, and MMP-13 are located in MV 
membranes and play a key role in matrix remodeling and propa-
gation of mineralization (5, 19, 20). In ECM, collagen fibrils and 
proteoglycans provide charged regions, which are favorable sites 
for accumulation of the calcium phosphate nanoparticle clusters 
that form in MVs. The amorphous apatite resulting from this 
accumulation transforms into structured and crystalline mineral 
following ECM associations (5). MVs interact with ECM proteins 
via their integrin receptors and surface motifs, such as CD9, 
CD63, and Hsp70 (5) (Figure 1). In addition to their remodeling 
potential and ECM binding, MVs in growth plate ECM can affect 
the proliferation and fate of resident cells, due to the activation 
of parathyroid hormones and gene-related peptide through their 
loaded proteins (5). This paracrine signaling property is similar to 
other subtypes of extracellular vesicles (EVs) ubiquitous to many 
cells and tissues.
It is worth mentioning that skepticism exists on the exist-
ence and role of MVs in bone growth and formation. Studies 
have suggested that calcification originates from cell death and 
debris, which nucleate mineral, and observations of MVs are 
attributed to sample preparation artifacts (21). In recent studies, 
however, isolation of MVs from chicken tibias using multiple 
centrifugations and application of microscopy techniques such 
as transmission electron microscopy on growth plate during 
bone formation have provided support for MVs as mediators 
of mineralization (22, 23). Furthermore, knockout of Stx4a, a 
regulatory factor for secretion of MVs, decreases number of MVs 
and leads to reduced bone mineral density (24). Recent interest 
in non-calcifying EVs (e.g., exosomes) and the related develop-
ment of assay techniques may build on the observational studies 
of the past and help clarify the derivation and function of MVs 
in the mineralization of hard tissues.
evs wiTH NON-OSTeOGeNiC ORiGiNS
Matrix vesicles represent one specific subtype of EVs. Generally, 
EVs function to maintain both intracellular and extracellular 
homeostasis. Two major pathways mediate EV release into the 
ECM: (i) via multivesicular bodies (MVB), containing several EVs 
wrapped by plasma membrane and (ii) through direct budding of 
a single EV from cellular plasma membrane (4). Depending on 
the release mechanism, EVs are generally referred to as exosomes 
and microparticles, respectively. Both EV types carry a subset of 
cargos representing their parental cell (11, 25). MVB trafficking 
and fusion/fission from the plasma membrane requires activity 
of Rab GTPases, specifically Rab27a, Rab27b, Rab35, and Rab11 
(26, 27). EV structure consists of a metabolically active mem-
brane with transmembrane proteins and an inner core, which 
typically carries RNAs, soluble proteins, and lipids (11, 25, 28). 
EVs often contain sets of small RNAs, such as miRNA, tRNA, 
mRNA, piRNA, snRNA, Y-RNA, and vault RNA, which can be 
protected from RNase degradation and encoded at target cells 
FiGURe 1 | Schematic of extracellular vesicles (EVs) contributing in calcific mineral formation. Osteogenic cells release EVs into ECM to nucleate bone or 
cardiovascular mineral. EV membranes contain a specific lipid profile that differs from the parent cell. Annexins on EVs facilitate Ca2+ entrance, and tissue 
non-specific alkaline phosphatase (TNAP) activity converts PPi to phosphate ions (Pi), thereby providing the necessary ionic components for mineralization. PiT-1 
transporters transfer Pi into the EV lumen. Coincidence of these ions and formation Ca2+–PS–Pi within the EV lead to mineral initiation. Membrane enzymes and 
proteins interact with and attach to the ECM, directing the localization of calcification. Figure created using Servier Medical Art images (http://smart.servier.com).
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(27, 29). The difference in RNA ingredients of parental cells and 
EV cargo demonstrates the selective mechanism of RNA loading. 
EV RNA cargo can serve as biomarker that indicate the pheno-
typic state of parental cells, as well as messengers that can interact 
with other cells (27). EVs play a key role in cell–cell interaction 
and data trafficking in both normal and pathological conditions. 
For instance, miRNA-enriched EVs from endothelial cells can 
regulate gene expression and resultant phenotypic transitions in 
smooth muscle cells (SMCs) (30). Divergence from normal physi-
ological conditions toward pathological ones induces release of 
dysfunctional EVs with pathologic cargo and may affect tissue 
homeostasis and cellular phenotypes (4). This section serves as 
a short primer on the complex mechanisms associated with EV 
release and cargo loading. These processes are reviewed in greater 
detail elsewhere (31–34). The current review focuses on EVs that 
play a direct role in depositing mineral in cardiovascular tissues. 
Current evidence, discussed in the following sections, suggests 
that these EVs share commonalities with both MVs and other EV 
populations, such as exosomes.
CALCiFYiNG evs iN CARDiOvASCULAR 
CALCiFiCATiON
Calcification contributes to pathological remodeling in dif-
ferent locations throughout the cardiovascular system, such 
as the arterial intima and media and the aortic valve (35, 36). 
Electron microscopy demonstrated the presence of needle-like 
hydroxyapatite nanocrystals in EVs extracted from atheroscle-
rotic lesions of apolipoprotein E-deficient mice (37). EVs released 
into the atherosclerotic lesion have a Ca/P ratio of 0.66, indicating 
incomplete calcification [compared to the ratio in normal adult 
murine bones of 1.71 (38)]. High resolution microcomputed 
tomography imaging revealed microcalcification in the fibrous 
cap of atherosclerotic plaques composed of calcified EV 
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aggregates (39, 40). These observations indicate a role for EVs 
in the formation and progression of cardiovascular calcification, 
but mechanistic studies demonstrating causality are difficult. 
One major challenge in EV research is to distinguish between 
different EV populations, such as calcifying EVs, MVs, exosomes, 
apoptotic bodies, and microparticles, due to their shared size and 
shape characteristics (41). Application of multiple and consecu-
tive centrifugations followed by size-based filtration and sucrose 
gradient-based ultracentrifugation to isolate EVs of known den-
sity have been used to separate different cellular-derived particles 
and EVs (25, 42). EVs with various sizes and densities pellet based 
on the centrifugation speed, i.e., large, medium, and small EVs 
precipitate at low, moderate, and high speeds, respectively (25). 
However, these techniques are often unable to separate the various 
EV populations. Calcifying EVs secreted by SMCs cultured under 
osteogenic conditions exhibit increased mass density compared to 
other EVs, likely due to mineral formation. Therefore, calcifying 
EVs precipitate more quickly under the application of ultracen-
trifugation (~100,000g) (41), permitting enrichment of these EVs 
and subsequent proteomic profiling (25, 41). Once proteomic 
fingerprints are established, membrane proteins (tetraspanins), 
ER-related proteins, mitochondrial proteins, exosomal markers, 
endosomal markers, and ECM factors (such as surface molecules 
and integrins) specific to various EV populations help map and 
separate EVs into subsets based on their origins (25).
In certain pathological conditions (such as chronic kidney 
disease), extracellular Ca2+/Pi concentrations increase, thereby 
cells release EVs with high levels of these ions (43). This may 
be in contrast to inflammation-driven osteogenic differentiation 
(e.g., in atherosclerosis). Release of EVs from cardiovascular 
cells with osteogenic phenotypes promotes mineralization via 
generation of free phosphate from sources such as ATP and 
pyrophosphate (44). Further, dystrophic mineral deposition 
resulting from cell death may also contribute to a significant 
portion of cardiovascular calcification (45). The diverse con-
tributors have led to confusion surrounding the mechanisms 
of cardiovascular calcification (46); however, numerous studies 
have demonstrated similarities between cardiovascular calci-
fication and bone metabolism (47–51). Annexins present on 
calcifying EVs play a dual role of Ca2+ uptake and counteracting 
the calcification inhibitory activity of fetuin-A during ectopic 
mineralization (4, 11). High phosphate imbalance present in 
chronic kidney disease may accelerate calcification nucleation 
in EVs (46). In this condition, TNAP activity may accelerate 
the calcification process in both non-osteogenic and osteogenic 
EVs through removing PPi, a competitive inhibitor to Ca2+ 
associations with Pi (39). EVs with calcifying potential may also 
contain imbalanced and dysfunctional miRNAs, which induce 
the gene expression and protein synthesis of osteogenic markers, 
such as RUNX2, Smad1, osterix, TNAP, chaperones, and pro-
inflammatory factors (4, 11). Unlike the physiological process 
of MV-mediated mineral deposition, however, calcification of 
EVs may inhibit their ability to reach their intended target cells, 
further promoting a loss in tissue homeostasis and pathological 
remodeling (52) (Figure 1).
Future works are needed to improve upon EV isolation 
techniques in order to reduce noise from non-calcifying EVs. 
Advancements in EV characterization tools may allow careful 
comparative studies to understand the similarities and differ-
ences between MVs and calcifying EVs liberated from the three 
reported cellular contributors to calcification in cardiovascular 
tissues: vascular SMCs, macrophages, and valvular interstitial 
cells (VICs). While these cell populations do not represent all 
cells involved in cardiovascular calcification, direct EV-related 
contributions to mineral nucleation from other cells remain 
unreported. Improvement of EV isolation and assay techniques 
may also allow for determination of the relative roles of the vari-
ous cell populations in the mineralization process.
Smooth Muscle Cell-Derived vesicles
Smooth muscle cells and osteoblasts share similar mesenchymal 
origins and under pathological stresses SMCs can exhibit an 
osteoblast-like phenotype (48). In a hyperphosphatemic envi-
ronment (e.g., chronic kidney disease) or inflammation-driven 
atherosclerosis, vascular SMCs upregulate expression of osteo-
genic differentiation genes (53) and release EVs enriched with 
pro-calcific biomarkers (44). Hyperphosphatemic and osteogenic 
conditions decrease circulating factors, such as fetuin-A (51) and 
matrix Gla protein (50), which inhibit extracellular mineraliza-
tion, but increase TNAP and annexins II and VI in SMC-derived 
EVs, which promote extracellular mineralization. Similar to its 
function in bone, TNAP activity leads to increased available Pi 
and reduction of mineralization inhibitors such as PPi (49). The 
formation of calcifying EVs begins with a series of intracellular 
trafficking processes that produce the EVs with calcification-
promoting factors. A specific trafficking protein, sortilin, is a key 
player in the formation of calcifying EVs secreted by vascular 
SMCs. Sortilin transports TNAP into SMC-derived EVs, thereby 
increasing EVs calcifying potential (49).
Materials science imaging techniques revealed that, once 
released into the ECM, SMC-derived calcifying EVs tend to aggre-
gate and form microcalcifications in areas with sparse collagen, 
whereas, large calcifications (larger than 200 µm) are bordered by 
dense collagen fibers (36). Large calcifications (macrocalcifica-
tions), shaped by accumulation of small calcifications (microcal-
cifications), gradually form mature mineral. Microcalcifications 
formed within the fibrous cap of vulnerable atherosclerotic 
plaques further potentiate plaque rupture, whereas larger mac-
rocalcifications beneath stable fibrous caps may promote plaque 
stability. EVs collected from SMCs cultured in pro-calcific 
conditions and incubated within an in  vitro collagen hydrogel 
system, mimicking aspects of atherosclerotic lesions, showed the 
progression of calcification from single calcifying EVs to EVs 
aggregation and fusion to the formation of microcalcifications 
to growth into large calcifications (36). Collagen acts as a scaffold 
to direct the shape and size of the calcifications generated from 
this growth process (36). Collagen fibrils, specifically type I and 
III in arteries, bind to EV membranes and mediate calcification 
propagation in the ECM (48). Figure 2 illustrates the mechanism 
by which EVs associate to form mineral within the tissue, begin-
ning with EV accumulation and aggregation to fusion and min-
eralization. In addition to binding and directing the calcification 
of EVs, collagen may also play a role in phenotypic changes and 
EV formation within SMCs (54). Discoidin domain receptor-1 
FiGURe 2 | Schematic of extracellular vesicle (EV)–collagen interaction to form microcalcifications in the atherosclerotic fibrous cap. Collagen degradation in 
vulnerable fibrous caps allows calcifying EVs to accumulate. The initial mineral nuclei forms within individual EVs and EV aggregation and fusion drives mineral 
maturation and growth (36).
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(DDR-1), a collagen receptor, regulates SMC phenotype by sens-
ing extracellular collagen. DDR-1-depleted SMCs exhibit elevated 
collagen production, EV release, and mineral deposition. DDR-1 
functions as a regulator of TGF-β signaling pathways, acting as 
a switch between pro-fibrocalcific and anti-fibrocalcific TGF-β 
signaling (54). Therapeutic strategies to control these pathways 
and prevent or reverse SMC-driven calcification will require a 
better understanding of the mechanisms that lead to their forma-
tion within the cell, nucleation of mineral outside the cell, and the 
role of the ECM in calcification propagation. SMC-derived EVs 
are the most studied type of calcifying EVs in cardiovascular tis-
sues and the mechanisms identified in these cells may help inform 
research into other cellular drivers of cardiovascular calcification.
viC-Derived vesicles
Valvular interstitial cell phenotypic changes play a vital role in 
ECM remodeling and mineral deposition that lead to calcific aor-
tic valve disease (55). VICs have a high phenotypic plasticity and 
can transform from a fibroblastic phenotype to myofibroblast- or 
osteoblast-like cells in response to pathological conditions, such 
as hyperphosphatemia and pro-inflammatory cytokines. VICs 
exhibit high sensitivity to their mechanical environment and 
undergo phenotypic changes in vitro in response to changes in 
substrate stiffness and mechanical stretch (55). VICs may also 
influence valvular endothelial cells (VECs) through EV secretion. 
Valve homeostasis depends on appropriate interactions between 
VECs and VICs (55, 56). This intercellular interaction occurs 
when VECs take up VICs-derived EVs containing perinuclear 
proteins (35). In calcifying milieu, VICs express osteogenic 
mRNAs of PiT-1, RUNX2, Msx2, and TNAP (57), and pro-
calcific VIC-derived EVs resemble MVs from chondrocytes 
and SMCs, demonstrating elevated annexins II, V, and VI (35). 
Similarly, immortalized rat VICs cultured in high calcium and 
phosphate media release EVs with elevated calcium and annexin 
VI, and electron microscopy revealed co-localization of annexin 
VI with EVs in calcified human aortic valves (57). Though aortic 
valve calcification constitutes a major unmet clinical problem, 
investigations into the extracellular mechanisms through which 
mineral nucleation and growth occurs remain scant. More 
studies are needed to understand the role of VIC EVs in this 
process and the similarities and differences between these EVs 
and the more well-studied SMC-derived EVs.
Macrophage-Derived vesicles
Atherosclerosis creates moderate hypoxia (2% oxygen) 
for local cells and leads to activation of pro-inflammatory 
responses such as Akt and β-catenin pathways in macrophages 
(58). Additionally, oxidized lipids, IL-6, and TNF-α (pro- 
inflammatory cytokines), and mechanical stimuli contribute 
to both increased inflammation and subsequent ectopic calci-
fication (59). Pro-inflammatory macrophages secrete elastolytic 
cathepsins and collagen-degrading MMPs (e.g., MMP-2 and -9), 
and the resultant proteolytic ECM degradation and remodeling 
causes atherosclerotic plaque instability and rupture, the lead-
ing cause of cardiovascular morbidity (60, 61). Inflammation 
precedes and may serve as a requisite step for the onset of both 
atherosclerotic and aortic valve calcification (61). Monocytes 
internalize forming minerals and secrete more inflammatory 
cytokines and intensify pathologic condition (62). Cytokines 
secreted by pro-inflammatory macrophages exacerbate calcifi-
cation by activating apoptosis or osteogenic pathways activa-
tion in SMCs and VICs (46). In addition to an indirect role in 
pro-calcific remodeling, macrophages can directly contribute to 
cardiovascular calcification through release of calcifying EVs in 
hyperphosphatemic milieu (46). Macrophage-derived calcifying 
EVs contain the tetraspanin exosomal markers of CD9, CD63, 
CD81, and TSG101 (28, 63). These EVs also exhibit immuno-
positivity for CD68 (63) (Figure 3A). In EVs released by mac-
rophages, calcium mineral nucleates on complexes containing 
S100A9 [a pro-inflammatory and pro-thrombotic factor (11)], 
PS, and annexin V on the EV membrane (4). Accumulation 
and aggregation of these EVs results in mineral growth within 
atherosclerotic plaques (Figure  3B). Of note, macrophages 
contribute to both vascular and valvular calcification; therefore, 
macrophage-derived EV calcification could provide a link 
between mineral depositions within these tissues.
CONCLUSiON
Calcifying EVs play an important role in the initiation and 
development of cardiovascular calcification. Though calcifying 
EVs in cardiovascular tissues appear to share commonalities 
with MVs, they seem to be derived from different origins within 
cells. The overlapping characteristics between EVs and MVs 
underscore the fact that research in cardiovascular calcification 
FiGURe 3 | Macrophage-derived extracellular vesicles (EVs) within 
atherosclerotic cap. (A) Macrophage-derived EVs contain the CD68 
glycoprotein (immunogold staining); (B) released EVs have various size and 
morphology and aggregate to build calcific mineral within the atherosclerotic 
fibrous cap (63).
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has been informed by pioneering research in bone physiol-
ogy. However, the noted differences between cardiovascular 
calcifying EVs and bone MVs warrant further investigation. 
The type and quality of mineral that forms appear different 
in the two tissues. Further, the appearance of calcific mineral 
in cardiovascular tissues associates strongly with a decrease in 
bone mineral density—a phenomenon known as the calcifica-
tion paradox (59). Studies into the differences between the 
fundamental building blocks of calcification—calcifying EVs 
in cardiovascular tissues and MVs in bone—may provide new 
insight into the observed divergence in mineral within these 
tissues and present therapeutic options that avoid unwanted 
off-target effects.
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